MINNEAPOLIS, Nov. 6, 2019 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of reagents and instruments for life science and clinical research, today announced the signing of an agreement with C4 Therapeutics, Inc. to acquire an exclusive license for the Achilles-TAG (aTAG) degradation platform. The license will make aTAG technology commercially available to the scientific research community for the first time.
The aTAG system is a chemical genetic application of the targeted protein degradation modality, harnessing the ubiquitin-proteasome system to induce selective degradation of specific proteins within a cell. The aTAG technology makes use of a newly developed heterobifunctional Degrader that selectively targets its corresponding degradation tag, which is based on the MTH1 protein. When a protein of interest is fused to the aTAG, treatment with this class of Degrader results in degradation of the aTAG-fusion protein. Researchers will be able to fuse the aTAG to their target protein of interest, and subsequently degrade the protein in their biological system.
This new technology offers the scientific community a new tool for validating the role of specific proteins in numerous disease states and physiological systems, in a rapid, tuneable and reversible manner.
Dave Eansor, President of Bio-Techne’s Protein Sciences Segment, commented, “The licensing agreement with C4 Therapeutics is highly significant as it allows the scientific community access to this cutting-edge technology. aTAG enables the study of the effects of a protein by deleting it from cells, both in vitro and in vivo, an exciting development for the field of Targeted Protein Degradation. Bio-Techne will continue to seek out innovative products for licensing, as well as develop new technologies in house, to help scientists make new discoveries and drive life science research forward.”
About Bio-Techne Corporation (NASDAQ: TECH)
|
CONTACT: |
David Clair, Senior Director, Corporate Development |
|
612-656-4416 |
SOURCE Bio-Techne Corporation
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…